Immunovant (IMVT) Stock Forecast & Price Target

Compare

916 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IMVT Analyst Ratings

Strong Buy

6 Buy

2 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Immunovant

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IMVT Stock 12 Month Forecast

Average Price Target

$39.57

▲(49.77% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is $39.57 with a high forecast of $54.00 and a low forecast of $28.00. The average price target represents a 49.77% change from the last price of $26.42.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","55":"$55","24.25":"$24.3","34.5":"$34.5","44.75":"$44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,24.25,34.5,44.75,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.75,25.153846153846153,27.557692307692307,29.96153846153846,32.36538461538461,34.76923076923077,37.17307692307692,39.57692307692308,41.980769230769226,44.38461538461539,46.78846153846153,49.19230769230769,51.59615384615385,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.75,24.043846153846154,25.337692307692308,26.63153846153846,27.925384615384615,29.21923076923077,30.513076923076923,31.806923076923077,33.10076923076923,34.394615384615385,35.68846153846154,36.98230769230769,38.276153846153846,{"y":39.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.75,23.153846153846153,23.557692307692307,23.96153846153846,24.365384615384617,24.76923076923077,25.173076923076923,25.576923076923077,25.98076923076923,26.384615384615383,26.78846153846154,27.192307692307693,27.596153846153847,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.07,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$54.00

Average Price Target$39.57

Lowest Price Target$28.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sam Slutsky

LifeSci Capital

$50

Buy

89.25%

Upside

Reiterated

12/12/25

Immunovant's Strategic Advancements and Promising Pipeline Drive Buy RatingYesterday, Roivant (Nasdaq: ROIV) hosted an Investor Day (LINK), providing a broad overview of the pipeline. As it relates to Immunovant (Nasdaq: IMVT), IMVT-1402 (FcRn inhibitor dosed via SC auto-injector) is posioned as a next-gen FcRn inhibitor designed to achieve deep, dose-dependent IgG suppression approaching ~80%, a level that current an-F cRn compet ors do not reach. This “deeper is be er” concept is central to Immunovant’s thesis for IMVT-1402, in that deeper IgG reducons have produced improved outcomes across several diseases thus far with batoclimab (ﬁrst-gen FcRn inhibitor), including Graves’ (GD), generalized myasthenia gravis (MG), and chronic demyelinang polyneuropathy (CIDP). The Company highlights that across eight autoimmune indicaons, late-stage clinical data has demonstrated a correlaon between the depth of IgG lowering and clinical beneﬁt.

Danielle Brill

Truist Financial

―

Hold

―

Reiterated

12/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Immunovant (NASDAQ: IMVT) and Harmony Biosciences Holdings (NASDAQ: HRMY)

Corinne Johnson

Goldman Sachs

$28

Hold

5.98%

Upside

Reiterated

12/12/25

Goldman Sachs Remains a Hold on Immunovant (IMVT)

Brian Cheng

J.P. Morgan

$33→$34

Buy

28.69%

Upside

Reiterated

11/19/25

J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)

Douglas Tsao

H.C. Wainwright

$22.82→$35

Buy

32.48%

Upside

Reiterated

11/14/25

H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT)

Eddie Hickman

Guggenheim

$44

Buy

66.54%

Upside

Reiterated

11/13/25

Guggenheim Keeps Their Buy Rating on Immunovant (IMVT)

Leland Gershell

Oppenheimer

$54

Buy

104.39%

Upside

Reiterated

11/11/25

Oppenheimer Sticks to Its Buy Rating for Immunovant (IMVT)

Jason Gerberry

Bank of America Securities

$30→$32

Buy

21.12%

Upside

Reiterated

11/10/25

Bank of America Securities Remains a Buy on Immunovant (IMVT)We reiterate Buy on our view that IMVT’s FcRn assets are underappreciated. Our new $32 PO (vs $30 prior)

Thomas Smith

Leerink Partners

$52

Buy

96.82%

Upside

Reiterated

09/03/25

Alex Thompson CFA

Stifel Nicolaus

$61→$50

Buy

89.25%

Upside

Reiterated

08/18/25

Immunovant (IMVT-Buy/lower TP $61 to $50; $15.17) Thompson F1Q26 Recap: IMVT-1402 Development is On-Track; Batoclimab Graves' 6-Month Remission in Sep'25 and Ph3 TED in 2H25

Derek Archila

Wells Fargo

$45

Buy

70.33%

Upside

Reiterated

08/12/25

Immunovant's Promising Pipeline and Strong Financial Position Signal a Buy Rating

Samantha Semenkow

Citi

$58→$57

Buy

115.75%

Upside

Reiterated

08/12/25

Immunovant's IMVT-1402: Promising Clinical Advancements and Strong Buy Rating Despite Increased Operational Costs

Ashwani Verma

UBS

$17→$18

Hold

-31.87%

Downside

Reiterated

07/29/25

Immunovant price target raised to $18 from $17 at UBSImmunovant price target raised to $18 from $17 at UBS

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Reiterated

07/25/25

Immunovant (IMVT) Gets a Buy from Cantor Fitzgerald

Dennis Ding

Jefferies

$20→$18

Hold

-31.87%

Downside

Reiterated

05/29/25

Jefferies Keeps Their Hold Rating on Immunovant (IMVT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sam Slutsky

LifeSci Capital

$50

Buy

89.25%

Upside

Reiterated

12/12/25

Danielle Brill

Truist Financial

―

Hold

―

Reiterated

12/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Immunovant (NASDAQ: IMVT) and Harmony Biosciences Holdings (NASDAQ: HRMY)

Corinne Johnson

Goldman Sachs

$28

Hold

5.98%

Upside

Reiterated

12/12/25

Goldman Sachs Remains a Hold on Immunovant (IMVT)

Brian Cheng

J.P. Morgan

$33→$34

Buy

28.69%

Upside

Reiterated

11/19/25

J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)

Douglas Tsao

H.C. Wainwright

$22.82→$35

Buy

32.48%

Upside

Reiterated

11/14/25

H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT)

Eddie Hickman

Guggenheim

$44

Buy

66.54%

Upside

Reiterated

11/13/25

Guggenheim Keeps Their Buy Rating on Immunovant (IMVT)

Leland Gershell

Oppenheimer

$54

Buy

104.39%

Upside

Reiterated

11/11/25

Oppenheimer Sticks to Its Buy Rating for Immunovant (IMVT)

Jason Gerberry

Bank of America Securities

$30→$32

Buy

21.12%

Upside

Reiterated

11/10/25

Bank of America Securities Remains a Buy on Immunovant (IMVT)We reiterate Buy on our view that IMVT’s FcRn assets are underappreciated. Our new $32 PO (vs $30 prior)

Thomas Smith

Leerink Partners

$52

Buy

96.82%

Upside

Reiterated

09/03/25

Alex Thompson CFA

Stifel Nicolaus

$61→$50

Buy

89.25%

Upside

Reiterated

08/18/25

Immunovant (IMVT-Buy/lower TP $61 to $50; $15.17) Thompson F1Q26 Recap: IMVT-1402 Development is On-Track; Batoclimab Graves' 6-Month Remission in Sep'25 and Ph3 TED in 2H25

Derek Archila

Wells Fargo

$45

Buy

70.33%

Upside

Reiterated

08/12/25

Immunovant's Promising Pipeline and Strong Financial Position Signal a Buy Rating

Samantha Semenkow

Citi

$58→$57

Buy

115.75%

Upside

Reiterated

08/12/25

Immunovant's IMVT-1402: Promising Clinical Advancements and Strong Buy Rating Despite Increased Operational Costs

Ashwani Verma

UBS

$17→$18

Hold

-31.87%

Downside

Reiterated

07/29/25

Immunovant price target raised to $18 from $17 at UBSImmunovant price target raised to $18 from $17 at UBS

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Reiterated

07/25/25

Immunovant (IMVT) Gets a Buy from Cantor Fitzgerald

Dennis Ding

Jefferies

$20→$18

Hold

-31.87%

Downside

Reiterated

05/29/25

Jefferies Keeps Their Hold Rating on Immunovant (IMVT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunovant

1 Month

xxx

Success Rate

24/41 ratings generated profit

Average Return

+4.10%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.54% of your transactions generating a profit, with an average return of +4.10% per trade.

3 Months

xxx

Success Rate

11/19 ratings generated profit

Average Return

+22.36%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +22.36% per trade.

1 Year

Thomas SmithLeerink Partners

Success Rate

11/19 ratings generated profit

Average Return

+53.63%

reiterated a buy rating 3 months ago

Copying Thomas Smith's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +53.63% per trade.

2 Years

xxx

Success Rate

10/19 ratings generated profit

Average Return

+62.73%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 52.63% of your transactions generating a profit, with an average return of +62.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMVT Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IMVT has received 7 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. IMVT average Analyst price target in the past 3 months is 39.57.

Each month's total comprises the sum of three months' worth of ratings.

IMVT Financial Forecast

IMVT Earnings Forecast

Next quarter’s earnings estimate for IMVT is -$0.72 with a range of -$0.83 to -$0.57. The previous quarter’s EPS was -$0.73. IMVT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year IMVT has Performed in-line its overall industry.

No data currently available

IMVT Sales Forecast

Next quarter’s sales forecast for IMVT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMVT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year IMVT has Performed in-line its overall industry.

IMVT Stock Forecast FAQ

What is IMVT’s average 12-month price target, according to analysts?

Based on analyst ratings, Immunovant’s 12-month average price target is 39.57.

What is IMVT’s upside potential, based on the analysts’ average price target?

Immunovant has 49.77% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IMVT a Buy, Sell or Hold?

Immunovant has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.

What is Immunovant’s price target?

The average price target for Immunovant is 39.57. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $54.00 ,the lowest forecast is $28.00. The average price target represents 49.77% Increase from the current price of $26.42.

What do analysts say about Immunovant?

Immunovant’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of IMVT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Immunovant (IMVT) Stock Forecast & Price Target

IMVT Analyst Ratings

IMVT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Immunovant

IMVT Analyst Recommendation Trends

IMVT Financial Forecast

IMVT Earnings Forecast

IMVT Sales Forecast

IMVT Stock Forecast FAQ

Detailed List of Analyst Forecasts